Federal Register / Vol. 62, No. 220 / Friday, November 14, 1997 / Notices 61129

GENERAL ACCOUNTING OFFICE

Advisory Council on Government

Auditing Standards; Notice of Meeting

The Advisory Council on Government

Auditing Standards will meet on

Monday, November 24, 1997, from 9:00

a.m. to 5:00 p.m., and Tuesday,

November 25, 1997, from 8:30 a.m. to

3:00 p.m., in room 7C13 of the General

Accounting Office building, 441 G St.,

NW., Washington, D.C.

The Advisory Council on Government

Auditing Standards will hold a meeting

to discuss issues that may impact

Government Auditing Standards. Any

interested person may attend the

meeting as an observer. Council

discussions and reviews are open to the

public.

For further information contact:

Marcia Buchanan, Assistant Director,

Government Auditing Standards, AIMD,

(202) 512–9321.

Dated: November 7, 1997.

Marcia B. Buchanan,

Assistant Director.

[FR Doc. 97–29911 Filed 11–13–97; 8:45 am]

BILLING CODE 1610–02–M

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

National Center for Health Statistics

(NCHS), Data Policy and Standards

Staff; Meeting

Name: ICD–9–CM Coordination and

Maintenance (C&M) Committee meeting.

Times and Dates: 9 a.m.–5 p.m. December

4, 1997; 9 a.m.–5 p.m. December 5, 1997.

Place: The Health Care Financing

Administration, Auditorium, 7500 Security

Boulevard, Baltimore, Maryland.

Status: Open to the public. In the interest

of security, non-government employees must

show a photo I.D., and sign-in to gain

entrance to the building.

Purpose: The ICD–9–CM Coordination and

Maintenance Committee will hold its final

meeting of the 1997 cycle on Thursday,

December 4 (Vol. 3 (Procedures)), and Friday,

December 5 (Volumes 1 and 2 (Diagnosis)).

The C&M meeting is a public forum for the

presentation of proposed modifications to the

International Classification of Diseases,

Ninth-Revision, Clinical Modification.

Matters To Be Discussed: Agenda items

will include:

Injury aftercare status

Palliative care

Ostomy complications

Late effects of CVA

Diabetes

Group B strep carrier status

Complications of artificial skin replacement

Update on ICD–10 Procedure Coding System

Platelet inhibitors

Artificial skin grafts

Stereotactic radiosurgery

Cardiomyostimulator

Percutaneous vascular puncture closure

Amniofusion

Injection or infusion of thrombolytic agent

Addenda

Agenda items are subject to change as

priorities dictate.

Contact Person for Additional Information:

Amy L. Blum, 301/436–7050 ext. 164

(diagnosis), or Amy Gruber 410/786–1542

(procedures), NCHS, CDC, Presidential

Building, 6525 Belcrest Road, Hyattsville,

Maryland 20782.

Dated: November 7, 1997.

John C. Burckhardt,

Acting Director, Management Analysis and

Services Office, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 97–29969 Filed 11–13–97; 8:45 am]

BILLING CODE 4160–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

The National Immunization Program

(NIP) of the Centers for Disease

Control and Prevention (CDC); Meeting

Name: Adolescent Immunization Meeting.

Time and Date: 7:30 a.m.–4 p.m. December

4, 1997.

Place: J.W. Marriott Hotel, Lenox, 3300

Lenox Road, NE Atlanta, Georgia 30326.

Telephone 404/262–3344, fax 404/262–8803.

Status: The meeting is open to the public

subject to the availability of conference room

space. The meeting will be a round table

discussion with public and private medical

providers and experts who deal with

adolescent health and immunization issues.

Written comments will be accepted during

the meeting or at the address below.

Attendees must provide and pay for their

own travel expenses.

Purpose: The meeting will bring together a

small group of public and private medical

experts, in adolescent health and

immunization, to collaborate with the CDC in

developing adolescent immunization disease

reduction and coverage goals/objectives.

Matters To Be Discussed: CDC speakers

will present background information; sample

goals/objectives; year 2000 and possible 2010

Healthy People objectives; and other

adolescent immunization health information.

In addition, CDC speakers will describe

vaccine-preventable diseases associated with

adolescents and estimated immunization

coverage levels.

Specific agenda items include adolescent

immunization coverage goals; coverage

estimates for childhood and adolescent

immunization; adolescent disease reduction

goals; epidemiology of vaccine preventable

diseases in adolescents; implementation

perspectives; HEDIS 3.0 adolescent

immunization measures; and managed care

organization adolescent immunization

policies.

Agenda items are subject to change as

priorities dictate.

Contact Person for More Information: Edith

Gary, Health Services Research and

Evaluation Branch, Immunization Services

Division, CDC, NIP, 1600 Clifton Road, NE,

M/S E–52, Atlanta, Georgia 30333. Telephone

404/639–8209, fax 404/639–8615, e-mail

exg1@cdc.gov.

Dated: November 7, 1997.

John C. Burckhardt,

Acting Director, Management Analysis and

Services Office, Centers for Disease Control

and Prevention (CDC).

[FR Doc. 97–29970 Filed 11–13–97; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 97N–0431]

Iatric Corp.; Revocation of Product

License for Coccidioidin, USP (BioCox)

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is announcing the

revocation of the biological product

license issued to Iatric Corp., Tempe,

AZ, for the manufacture of

Coccidioidin, USP (BioCox). In a letter

to FDA dated May 13, 1997, Iatric Corp.

voluntarily requested revocation of its

product license for Coccidioidin, USP

(BioCox). In a letter dated June 25, 1997,

FDA informed the firm that its product

license for Coccidioidin, USP (BioCox)

was revoked.

DATES: The revocation of the product

license became effective June 25, 1997.

FOR FURTHER INFORMATION CONTACT:

Astrid L. Szeto, Center for Biologics

Evaluation and Research (HFM–17),

Food and Drug Administration, 1401

Rockville Pike, Rockville, MD 20852–

1448, 301–827–6210.

SUPPLEMENTARY INFORMATION: FDA has

revoked the product license issued to

Iatric Corp., 2330 South Industry Park

Ave., Tempe, AZ 85282, for the

manufacture of Coccidioidin, USP

(BioCox).

FDA inspected Iatric Corp. on April 7

through 11, 1997. The inspection of the

facility revealed serious deviations from

applicable Federal regulations. The

inspection also included a concurrent

investigation concerning the interstate

distribution of the product. The

deficiencies noted included, but were

not limited to, the following: (1) Failure